Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can PSA velocity predict risk of death in men with prostate cancer?

Nature Clinical Practice Urology volume 4, pages 410–411 (2007)Cite this article

boxed-textCarter HB et al. (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98: 1521–1527

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Welch HG et al. (2005) Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 97: 1132–1137

    Article  Google Scholar 

  2. Carter HB et al. (1992) Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267: 2215–2220

    Article  CAS  Google Scholar 

  3. D'Amico AV et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125–135

    Article  CAS  Google Scholar 

  4. D'Amico AV et al. (2005) Pretreatment PSA velocity and the risk of death from prostate cancer following external beam radiation therapy. JAMA 294: 440–447

    Article  CAS  Google Scholar 

  5. Thompson IM et al. (2006) Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98: 529–534

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. H Lilja is a Member and Attending Research Clinical Chemist in the Departments of Clinical Laboratories, Surgery (Division of Urology), and Medicine (Genitourinary Oncology) and F O'Brien is a Fellow in Urological Oncology at Memorial Sloan–Kettering Cancer Center in New York, NY, USA.,

    Hans Lilja & Frank O'Brien

Authors
  1. Hans Lilja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank O'Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans Lilja.

Ethics declarations

Competing interests

H Lilja has declared that he is a patent holder of free PSA and hK2 assays. Dr Frank O'Brien has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lilja, H., O'Brien, F. Can PSA velocity predict risk of death in men with prostate cancer?. Nat Rev Urol 4, 410–411 (2007). https://doi.org/10.1038/ncpuro0811

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0811

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing